Short Interest in MariMed Inc. (OTCMKTS:MRMD) Decreases By 85.1%

MariMed Inc. (OTCMKTS:MRMD) saw a large decline in short interest in the month of December. As of December 31st, there was short interest totaling 5,595 shares, a decline of 85.1% from the December 15th total of 37,428 shares. Based on an average trading volume of 4,605,275 shares, the days-to-cover ratio is presently 0.0 days. Approximately 0.0% of the company’s shares are sold short. Approximately 0.0% of the company’s shares are sold short. Based on an average trading volume of 4,605,275 shares, the days-to-cover ratio is presently 0.0 days.

Wall Street Analyst Weigh In

MRMD has been the subject of a number of recent research reports. Zacks Research upgraded shares of MariMed from a “strong sell” rating to a “hold” rating in a report on Thursday, January 1st. Ventum Cap Mkts cut MariMed from a “strong-buy” rating to a “hold” rating in a report on Friday, November 7th. One analyst has rated the stock with a Strong Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy”.

MariMed Stock Performance

Shares of OTCMKTS MRMD traded up $0.00 during mid-day trading on Monday, hitting $0.10. 392,809 shares of the company were exchanged, compared to its average volume of 1,586,082. The company has a quick ratio of 0.35, a current ratio of 1.06 and a debt-to-equity ratio of 1.34. The firm has a market cap of $37.98 million, a price-to-earnings ratio of -2.40 and a beta of 1.04. MariMed has a 1-year low of $0.07 and a 1-year high of $0.23. The stock has a 50 day simple moving average of $0.09 and a 200-day simple moving average of $0.12.

MariMed (OTCMKTS:MRMD) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.01) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.01). The firm had revenue of $40.76 million during the quarter, compared to analysts’ expectations of $42.15 million. MariMed had a negative return on equity of 14.67% and a negative net margin of 11.36%.

About MariMed

MariMed Inc is a multi‐state cannabis company focused on the development, ownership and operation of regulated facilities for the medical and adult‐use cannabis markets. Headquartered in New Bedford, Massachusetts, the company cultivates, processes and dispenses cannabis through an integrated business model that encompasses cultivation, formulation, manufacturing and retail operations. MariMed operates under its own licensed brands and through strategic partnerships to expand its presence across the United States.

The company’s product portfolio includes branded flower, pre‐rolls, vaporizer cartridges, tinctures, edibles and topicals designed to meet a range of consumer and patient needs.